OP43L
Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1)
lyophilized, clone DO-1, Calbiochem®
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.43
UNSPSC Code:
12352203
Clone:
DO-1, monoclonal
Species reactivity:
feline, human
Application:
—
Citations:
10
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
DO-1, monoclonal
form
lyophilized
does not contain
preservative
species reactivity
feline, human
should not react with
mouse, rat
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
dilution
(Frozen sections (1 µg/mL)
Gel Shift
Immunoblotting (0.1 µg/mL)
Immunocytochemistry (1-2.5 µg/mL)
Immunoprecipitation (1 µg/mL)
Paraffin sections (1 µg/mL, pepsin, heat or pressure cooker pre-treatment required))
isotype
IgG2a
shipped in
ambient
Quality Level
Gene Information
human ... TP53(7157)
target post-translational modification
unmodified
正在寻找类似产品? 访问 产品对比指南
General description
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with X63Ag8.653 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) is validated for use in Frozen sections, Gel Shift, Immunoblotting, ICC, IP, Paraffin sections for the detection of p53 (Ab-6) (Pantropic).
Immunogen
Epitope: Within amino acids 21-25 of human p53
Human
wild type, recombinant, human p53
Application
Frozen sections (1 µg/ml; see application references)
Gel Shift (see comments)
Immunoblotting (0.1 µg/ml; see application references)
Immunocytochemistry (1-2.5 µg/ml; see application references)
Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Gel Shift (see comments)
Immunoblotting (0.1 µg/ml; see application references)
Immunocytochemistry (1-2.5 µg/ml; see application references)
Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Physical form
Lyophilized from a volatile buffer, 100 µg BSA.
Preparation Note
We recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Reconstituted product will be more stable if 0.1% sodium azide is added (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least two hours. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage.
Analysis Note
Negative Control
SK-OV-3 cells or normal skin tissue
SK-OV-3 cells or normal skin tissue
Positive Control
A431 cells or breast carcinoma tissue
A431 cells or breast carcinoma tissue
Other Notes
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Recognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. For gel shift assay, resuspend in 100 µl of buffer. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Antibody should be titrated for optimal results in individual systems.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
未找到合适的产品？
试试我们的产品选型工具.
存储类别
11 - Combustible Solids
wgk
WGK 1
Darren M Hutt et al.
Methods in molecular biology (Clifton, N.J.), 1510, 77-91 (2016-10-21)
Gene expression is regulated in part through the reversible acetylation of histones, by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC). HAT activity results in the addition of acetyl groups on the lysine residues of histone tails leading
Masaki Kobayashi et al.
Oncotarget, 11(18), 1653-1665 (2020-05-15)
Poly (ADP-ribose) polymerase 1 (PARP1) plays important roles in single strand DNA repair. PARP1 inhibitors enhance the effects of DNA damaging drugs in homologous recombination-deficient tumors including tumors with breast cancer susceptibility gene (BRCA1) mutation. Nutlin-3a, an analog of cis-imidazoline
Sindy Sohr et al.
Cell cycle (Georgetown, Tex.), 10(21), 3758-3767 (2011-10-29)
Successful pregnancy requires a functionally normal blastocyst encountering a receptive maternal endometrium. Interestingly, the cell cycle regulator and tumor suppressor p53 has been reported to support reproduction in mice by regulating the expression of the leukemia inhibitory factor gene in
E E Hoskins et al.
Oncogene, 27(35), 4798-4808 (2008-04-29)
Fanconi anemia (FA) is a genome instability syndrome that is characterized by progressive bone marrow failure and a high risk of cancer. FA patients are particularly susceptible to leukemia as well as squamous cell carcinomas (SCCs) of the head and
Yan Degenhardt et al.
Molecular cancer therapeutics, 9(7), 2079-2089 (2010-06-24)
Polo-like kinases are a family of serine threonine kinases that are critical regulators of cell cycle progression and DNA damage response. Predictive biomarkers for the Plk1-selective inhibitor GSK461364A were identified by comparing the genomics and genetics of a panel of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持